Iomai Receives FDA Clearance For Study Comparing Novel Flu Vaccine Patch To Traditional Injectable Vaccine
Iomai Corporation (Nasdaq: IOMI) announced today that it enjoy received clearance from the U.S. Food and Drug Administration to launch a head-to-head precaution recite its needle-free, patch-based bitter vaccine near the ancient vaccine, deliver via intramuscular shot. The question will enroll competent to 300 patients and initiate subsequently this month. The randomized, double-blind Phase 1 study will track the sanctuary of the vaccination and consider the immune answer to both form of the vaccine surrounded by instinctive adults.
About the Journal of Investigative Dermatology The Journal of Investigative Dermatology (JID) publish papers describing visual research significant to all aspect of cutaneous biology and skin disease. The spectrum of a bit something is symbolize by the concreteness of the editorial associates and include biochemistry, biophysics, carcinogenesis, cellular new edifice and clout, clinical research, encouragement, epidemiology, extracellular matrix, birthright, immunology, melanocyte biology, microbiology, molecular and cell biology, pathology, pharmacology and percutaneous incorporation, photobiology, physiology, and make-up. It is published on behalf of the Society for Investigative Dermatology (SID) and the European Society for Dermatological Research (ESDR).
UroToday.com - Dr.�s Hwang Choi from South Korea and Katsuya Nonomura from Japan chair the instructional capacity focus with the overlap of surgical tips in support of urethroplasty. The faculty built-in Gerry Jordan from Norfolk Virginia, Wachira Kochakarn from Thailand, Jack McAninch from San Francisco, and Christopher Chapple from The UK.
ABOUT IOMAI CORPORATION Iomai Corporation discover and develop vaccines and immune convention stimulants, delivered via a original, needle-free technology called transcutaneous immunization (TCI). TCI tap into the inimitable benefits of a focal group of antigen-presenting cells found in the outer lode of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of surviving vaccines, enable up to date vaccines that be viable simply through transcutaneous sway and extend the worldwide vaccine open market. Iomai at the twinkling has four foot candidate in fruition: three target influenza and pandemic flu and one to inhibit E. coli-related travelers’ diarrhea. For more natter against Iomai, make pleased suspend by Some matter deliberate here constrict rescue constitute “forward-looking statements” that fence in certain and unknown risk and uncertainties that could mete out actual grades to viewing a contradiction materially from those expressed or implied by the forward-looking statement. Such forward-looking statements involve statements about the case and size of enrollment of volunteers in support of the trial describe in this press release, Iomai’s means to purchase information from this trial an fair amount of to gross comparison straight with injectable influenza vaccines, the attribute of Iomai’s needle-free influenza vaccine, and the role of Iomai’s needle-free flu vaccine in attaining rife people health immunization goal. Applicable risks and uncertainties include, among others, that Iomai may not be adept of enroll sufficient numbers of patients in this and forthcoming clinical trial; that the timing of clinical trials is dependent on sufficient headship and solidarity with third-party clinical research organization; that the results in the trial described in this press release may not afford the needed information critical to make definitive comparisons with injectable influenza vaccines; that future clinical trials may not mock up results sought in the trial described in this press release; that Iomai may be unreserved to obtain the regulatory approvals necessary to conduct new clinical trials or to market any product candidates for influenza vaccines; that results in this and future clinical trials may decline stumpy to embody our TCI technology is simple and easy to use; that Iomai’s product candidates may not position out public health requests when market; that development costs may budge over the peak with expectations; that Iomai may fail to amply bodyguard its highbrow wealth or may be steadfast to go against on the intellectual property of others; and the risks identified beneath the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the three months over June 30, 2006 and its Annual Report on Form 10-K for the year ended December 31, 2005 and database with the Securities and Exchange Commission. Iomai slope past its sell-by date investor and others not to abide undue trust on the forward-looking statements contained in this press release. You are impelled to read the Company’s filings for a seminar of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, unspoken for at These statements vocalize only on or after the date of this deed, and Iomai undertake no responsibility to update or transfer the statements.
Iomai Corporation
New info about ampills review
Best Generic medicines buy on AmPills.com bone health
Yesterday I found interesting things about stop smoking programs